Shield Therapeutics plc a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), notes the recent publication in Nephrology… read more.
GlaxoSmithKline announced the FDA Oncologic Drugs Advisory Committee (ODAC) voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients… read more.
Arcutis Biotherapeutics, Inc. ,announced that The New England Journal of Medicine has published positive results from a Phase IIb trial of its investigational drug topical roflumilast cream for… read more.
Merck Inc., announced that the FDA has accepted for priority review the New Drug Application (NDA) for BAY 1021189 (vericiguat), an orally administered soluble guanylate cyclase (sGC) stimulator,… read more.
GlaxoSmithKline announced the FDA Oncologic Drugs Advisory Committee (ODAC) voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients… read more.
Moderna, Inc. announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of… read more.
Rigel Pharmaceuticals, Inc. announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase… read more.
Detailed results from the positive Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate… read more.
Mallinckrodt Plc announced that the Cardiovascular And Renal Drugs Advisory Committee of the U.S. FDA voted to recommend approval for its investigational agent terlipressin to treat adults with… read more.
The Alzheimer’s Clinical Trials Consortium (ACTC), Eisai Co., Ltd. and Biogen Inc., announced that a new Phase III clinical study (AHEAD 3-45) of BAN 2401, an antiamyloid beta… read more.
The Alzheimer’s Clinical Trials Consortium (ACTC), Eisai Co., Ltd. and Biogen Inc., announced that a new Phase III clinical study ?AHEAD 3-45) of BAN 2401, an antiamyloid beta… read more.
Ovid Therapeutics Inc. and Angelini Pharma S.p.A. announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV 101 (gaboxadol) for the potential… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
